Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 15;25(1):42.
doi: 10.1007/s11892-025-01590-6.

From Type 2 Diabetes Mellitus To Diabetic Cardiomyopathy - A Systematic Review On The Role Of MicroRNA

Anna Żarek-Starzewska  1 , Dominika Klimczak-Tomaniak  2 , Amelia Mądrecka  1 , Grażyna Sygitowicz  3 , Maciej Janiszewski  4 , Marek Kuch  1
Affiliations

From Type 2 Diabetes Mellitus To Diabetic Cardiomyopathy - A Systematic Review On The Role Of MicroRNA

Anna Żarek-Starzewska et al. Curr Diab Rep. .

Abstract

Purpose of review: Diabetes mellitus (DM) is a growing global health concern, and diabetic cardiomyopathy (DCM) affects up to 12% of individuals with diabetes, leading to myocardial hypertrophy, ventricular remodeling, and contractile dysfunction, ultimately progressing to heart failure (HF). This review explores the role of microRNAs (miRNAs) in DCM development and their potential as diagnostic and therapeutic biomarkers.

Recent findings: MicroRNAs, short single-stranded non-coding RNAs, are key regulators of various pathophysiological processes in DCM. By modulating gene expression, they influence critical signaling pathways involved in inflammation, apoptosis, pyroptosis, oxidative stress, and fibrosis, all of which contribute to DCM progression. Emerging research suggests that miRNAs could serve as early-stage biomarkers for asymptomatic DCM and may offer novel therapeutic targets. This systematic review compiles current findings from both animal and human studies on the role of miRNAs in DCM. It highlights their potential in the early diagnosis and treatment of DCM, underscoring the need for further research to translate these insights into clinical applications.

Keywords: Diabetes; Diabetic cardiomyopathy; Heart failure; MiRNA; MicroRNA.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical Approval: This article does not contain any studies with human or animal subjects performed by any of the authors. Conflict of Interest: The authors declare no competing interests. Human and Animal Rights and Informed Consent: This article does not contain any studies with human or animal subjects performed by any of the authors.

Figures

Fig. 1
Fig. 1
The Prefered Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) scheme. DM1-Diabetes mellitus type 1, CVD-Cardivascular diseases
Fig. 2
Fig. 2
Key Signalling Pathways Driving the Development of Diabetic Cardiomyopathy
See this image and copyright information in PMC

References

    1. Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al KJ. Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020;10(1):107–11. 10.2991/jegh.k.191028.001. - DOI - PMC - PubMed
    1. Tinajero MG, Malik VS. An Update on the Epidemiology of Type 2 Diabetes: A Global Perspective. Endocrinol Metab Clin North Am. 2021;50(3):337–55. 10.1016/j.ecl.2021.05.013. - DOI - PubMed
    1. Leon BM, Maddox TM. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes. 2015;6(13):1246–58. 10.4239/wjd.v6.i13.1246. - DOI - PMC - PubMed
    1. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834–44. 10.1056/NEJMoa1607141. - DOI - PubMed
    1. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004;27(8):1879–84. 10.2337/diacare.27.8.1879. - DOI - PubMed

Publication types

MeSH terms